Loading...
XCSE
ALK B
Market cap7.20bUSD
Dec 04, Last price  
229.40DKK
1D
-0.78%
1Q
12.89%
Jan 2017
398.70%
Name

ALK-Abello A/S

Chart & Performance

D1W1MN
XCSE:ALK B chart
P/E
56.66
P/S
8.34
EPS
4.05
Div Yield, %
—
Shrs. gr., 5y
0.32%
Rev. gr., 5y
11.08%
Revenues
5.54b
+14.78%
1,217,000,0001,489,000,0001,652,000,0001,784,000,0001,935,000,0002,140,000,0002,348,000,0002,345,000,0002,244,000,0002,433,000,0002,569,000,0003,005,000,0002,910,000,0002,915,000,0003,274,000,0003,491,000,0003,916,000,0004,511,000,0004,824,000,0005,537,000,000
Net income
815m
+67.70%
4,302,000,00024,000,000140,000,00095,000,000118,000,000128,000,000200,000,00054,000,00061,000,000181,000,000344,000,000270,000,000-158,000,000-170,000,000-50,000,00025,000,000219,000,000335,000,000486,000,000815,000,000
CFO
1.21b
+81.86%
175,000,00060,000,000362,000,000189,000,000260,000,000274,000,000431,000,00091,000,000146,000,000320,000,000183,000,000405,000,000-387,000,000-95,000,000132,000,000301,000,000468,000,000416,000,000667,000,0001,213,000,000
Dividend
Mar 16, 20175 DKK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
URL
https://www.alk.net/
IPO date
Jan 01, 1961
Employees
2,727
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT